- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00571298
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma
RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second intracavitary chemotherapy can be accomplished safely.
PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.
Study Overview
Status
Conditions
Detailed Description
- This is a dose escalation study of gemcitabine with a fixed dose of cisplatin
- Patients will undergo cytoreductive surgery, which entails the removal of the inner and outer lining of the lung (pleurectomy/decortication) with or without the lung itself (extrapleural pneumonectomy), including the lining overlying the pericardium and diaphragm. Resection of the pericardium and diaphragm are occasionally necessary to remove all visable tumor. This surgery is part of standard care for malignant pleural mesothelioma.
- After surgery, a one hour lavage with heated cisplatin and or gemcitabine will be administered to the hemithorax (and abdominal regions if the diaphragm is no longer present).
- Patients will remain hospitalized until they have recovered from surgery (usually 7-14 days).
- Patients will return to the hospital during the first month after their surgery to be evaluated by the medical staff.
- Dose escalation: 1) Three patients will be treated at the first dose level of gemcitabine. Labs will be monitored on a weekly basis, including a CBC, Chem-7, and LFT's. In the absence of developing dose-limiting toxicity (DLT) among the first 3 patients treated, dosages can be escalated. DLT will be defined as any grade 3 or higher renal toxicity, thrombocytopenia or other grade 3 toxicity not related to surgery 2) If none of these 3 patients have any toxicity, we will proceed to the next level of gemcitabine. 3) If DLT occurs in 1 of 3 patients at a given dose level, then 3 additional patients are added at that dose (for a total of 6 at this level)If no DLT occurs, we will proceed to the next level of gemcitabine. If DLT occurs in another patient, this dose is considered the maximum tolerated dose (MTD). 4) At any dose, 3 cases of DLT lead to discontinuation of recruitment at that dose and enrollment of 3 additional patients at a lower dose.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically-proven diagnosis of stages I to III malignant mesothelioma of the pleura and negative mediastinal N2 lymph nodes (Malignancy is confined to the affected hemithorax)
- Adequate organ function including the following: adequate cardiac function, pulmonary function, renal and hepatic function and bone marrow reserve
- Adequate overall physical activity
- Surgical candidate for cytoreductive surgery
Exclusion Criteria:
- Extended disease outside the ipsilateral hemithorax as proven histologically, radiologically and/or intraoperatively
- Have received chemotherapy and or radiation therapy within the last 3 years at the time of study entry
- Serious concomitant systemic disorders
- Second active primary malignancy (to exclude non- melanoma skin cancer)
- Pregnancy at the time of the operation
- Psychiatric or addictive disorder which would preclude obtaining informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Extrapleural pneumonectomy (EPP)
This is dose escalation 3+3 study design.
All the patients meet the eligibility criteria and then sign the informed consent.
Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection.
Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
|
Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
Given intravenously immediately at the end of perfusion chemotherapy
|
EXPERIMENTAL: Pleurectomy/Decortication (P/DC)
This is dose escalation 3+3 study design.
All the patients meet the eligibility criteria and then sign the informed consent.
Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection.
Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
|
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
Given intravenously immediately at the end of perfusion chemotherapy
Resection of the lining of the lung (pleura), while the lung remains intact.
|
EXPERIMENTAL: Tumor Debulking (TD)
This is dose escalation 3+3 study design.
All the patients meet the eligibility criteria and then sign the informed consent.
Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection.
Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
|
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given after the tumor is removed as a bath (perfusion) for one-hour
Other Names:
Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
Given intravenously immediately at the end of perfusion chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity.
Time Frame: 2 years
|
2 years
|
To study the pharmacokinetics of gemcitabine and cisplatin combination administered in this way.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenoma
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Anti-Bacterial Agents
- Antioxidants
- Antidotes
- Antitubercular Agents
- Chelating Agents
- Sequestering Agents
- Radiation-Protective Agents
- Gemcitabine
- Cisplatin
- Amifostine
- Sodium thiosulfate
Other Study ID Numbers
- 07-091
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Pleural Mesothelioma
-
NRG OncologyNational Cancer Institute (NCI)TerminatedPleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...United States, Canada
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...United States
-
RS Oncology LLCRecruitingMesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; LungUnited Kingdom
-
Health Pharma Professional ResearchWithdrawnMalignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, UnresectableMexico
-
National Cancer Institute (NCI)TerminatedEpithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural MesotheliomaUnited States
-
National Cancer Institute (NCI)WithdrawnMalignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)United States
-
Royal Marsden NHS Foundation TrustMerck Sharp & Dohme LLCTerminatedAdvanced Malignant Pleural MesotheliomaUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant MesotheliomaUnited States
-
Abramson Cancer Center at Penn MedicineRecruitingEpitheliod Malignant Pleural MesotheliomaUnited States
Clinical Trials on Extrapleural pneumonectomy (EPP)
-
AHEPA University HospitalCompletedMortality | Patient Outcome Assessment | Morbidity
-
University of Milano BicoccaAzienda Ospedaliera San Gerardo di MonzaCompletedCOVID-19 | Pneumothorax | Hemothorax | Abscess | Surgical Complication | Empyema, Pleural | ThoracicItaly, United States, Brazil, India, United Kingdom
-
Boston CollegeUniversity of Georgia; Innovations for Poverty Action; Caritas Freetown; German...CompletedMental Health Disorder | Mental Health Impairment | Psychosocial ProblemSierra Leone
-
Boston CollegeUniversity of Georgia; Caritas Freetown; German Society for International CooperationCompletedMental Health Disorder | Mental Health Impairment | Psychosocial Impairment | Emotional DysfunctionSierra Leone
-
Jiexiong FengNot yet recruitingChildren | Thoracoscopic Surgery | Indocyanine Green | Congenital Pulmonary Airway Malformation | Pulmonary SequestrationChina
-
Cairo UniversityCompleted
-
Virginia Commonwealth UniversityI-FlowTerminatedTHoracotomyUnited States
-
SVS Institute of Dental SciencesUnknown
-
Jianghui XuCompleted
-
Dr. Aslan Private Perio CenterCompleted